Every rule your marketing answers to.

Warrant reviews your marketing against 3,388 rules from 1,267 regulators across 11 countries. Every flag is cited to its source. Search the full library below.

Coverage includes the FTC, FDA, CFPB, SEC, FINRA, NCUA, FDIC, OCC, NAIC, and regulators from all 50 U.S. states, the European Union, Canada, and more.

Get a free homepage compliance scan

Regulation guides

FDA OPDP Boxed Warning Marketing Standards

Promotion of drugs with a boxed warning must convey the boxed-warning risk with prominence comparable to benefit claims, and reminder ads are not permitted for these drugs.

21 CFR 202.1(e)(1), (e)(2)(i), (e)(5)(ii), (e)(7)(viii); 21 CFR 201.57(c)(1); 21 U.S.C. 352(n)

FDA OPDP DTC Pharma Fair Balance Requirements

Prescription drug ads that name a drug and its use must present risk information with prominence comparable to benefit claims and must not overstate efficacy or safety.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6), (e)(7)

FDA OPDP Help-Seeking / Disease Awareness Ads

Disease-awareness ads from drug firms may discuss a condition and urge a doctor visit but must not name, cue or point to a specific drug; if they do, they become product ads needing risk information.

21 CFR 202.1; 21 U.S.C. 352(n); FDA Draft Guidance, Help-Seeking and Other Disease Awareness Communications (Jan. 2004) secs. III.A, IV

FDA OPDP Off-Label Promotion Prohibition

Drug firms may not promote prescription drugs for unapproved uses; scientific information on unapproved uses may go to HCPs only if separate from promotion and accompanied by the disclosures in FDA's 2025 guidance.

21 U.S.C. 352(a), (f), (n); 21 CFR 202.1(e)(4)(i)(a), (e)(6)(i), (e)(6)(xi); 21 CFR 201.128; FDA SIUU Q&A Guidance (Jan. 2025) sec. V, Q2-Q5

FDA OPDP Patient Testimonial Marketing Standards

Patient testimonials for prescription drugs must not convey atypical or off-label results or downplay risk, and product-claim testimonials need risk information.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(1), (e)(4)(i)(a), (e)(5)(ii), (e)(6)

FDA OPDP Pediatric / Geriatric Pharma Marketing

Prescription drug promotion must not depict or target age groups outside the approved indication and must include labeled age-specific risks when targeting that group.

21 U.S.C. 352(a), (n); 21 CFR 202.1(e)(5)(ii), (e)(6)(i), (e)(6)(xix), (e)(7)(x); 21 CFR 201.57(c)(9)(iv)-(v)

FDA OPDP Reminder Ads — No Indication Allowed

Reminder ads may name a prescription drug with limited facts but may not state or imply its use or make claims, and are not allowed for drugs with boxed warnings.

21 CFR 202.1(e)(2)(i); 21 CFR 201.100(f)

FDA OPDP Social Media Pharma Marketing

Social and character-limited posts that name a prescription drug and its benefit must state the most serious risks in the post and link to complete risk information.

21 CFR 202.1(e)(1), (e)(5)(ii), (e)(6)(i), (e)(6)(iv); 21 U.S.C. 352(a), (n)

Browse by category

Browse by jurisdiction

Browse by regulator